Prostatype Genomics AB (PROGEN) — Financial Flexibility Index
Prostatype Genomics AB (PROGEN) has a Financial Flexibility Index of -1.15x as of June 2025. Free cash flow of Skr-8.43 Million (operating CF Skr-8.54 Million minus capex Skr114.50K) represents -1% of total liabilities (Skr7.36 Million). Also explore Prostatype Genomics AB equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Prostatype Genomics AB Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Prostatype Genomics AB across 8 annual periods. Check PROGEN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Prostatype Genomics AB (2016–2024)
Year-by-year free cash flow to debt coverage for Prostatype Genomics AB. For the full company profile including market capitalisation, see Prostatype Genomics AB market capitalisation.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -4.33x | Skr-36.85 Million | Skr-44.71 Million | Skr8.50 Million | ▼ -417.1% |
| 2023 | -0.84x | Skr-20.58 Million | Skr-29.14 Million | Skr24.55 Million | ▲ +85.5% |
| 2022 | -5.77x | Skr-27.69 Million | Skr-27.69 Million | Skr4.80 Million | ▼ -82.6% |
| 2021 | -3.16x | Skr-13.58 Million | Skr-16.08 Million | Skr4.30 Million | ▼ -15.6% |
| 2020 | -2.73x | Skr-14.69 Million | Skr-14.71 Million | Skr5.37 Million | ▼ -287.4% |
| 2018 | -0.71x | Skr-6.37 Million | Skr-9.63 Million | Skr9.03 Million | ▼ -807.7% |
| 2017 | -0.08x | Skr-1.05 Million | Skr-5.71 Million | Skr13.49 Million | ▲ +96.1% |
| 2016 | -2.01x | Skr-9.60 Million | Skr-9.63 Million | Skr4.79 Million | — |